Risk factors for classic and de novo late acute GVHD
| . | Classic . | Late . | ||
|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Recipient age (y), category | ||||
| <55 | 1 | Ref | 1 | Ref |
| ≥55 | 1.00 (0.87-1.16) | .960 | 1.84 (1.19-2.88) | .007 |
| Sex mismatch | ||||
| Other | 1 | Ref | 1 | Ref |
| Female-to-male | 0.98 (0.83-1.15) | .780 | 1.53 (1.09-2.14) | .014 |
| Primary disease | ||||
| Acute leukemia | 1 | Ref | 1 | Ref |
| MDS/MPN | 1.12 (0.97-1.28) | .120 | 1.02 (0.73-1.41) | .920 |
| Malignant lymphoma | 1.08 (0.87-1.34) | .480 | 1.00 (0.54-1.84) | .990 |
| Other | 1.00 (0.82-1.22) | .530 | 1.02 (0.61-1.70) | .930 |
| Disease risk | ||||
| Standard | 1 | Ref | 1 | Ref |
| High | 1.05 (0.91-1.21) | .530 | 0.89 (0.58-1.35) | .570 |
| Donor type | ||||
| HLA-MRD | 1 | Ref | 1 | Ref |
| HLA-MUD | 1.56 (1.34-1.81) | < .001 | 0.77 (0.55-1.07) | .120 |
| HLA-MMUD | 1.97 (1.55-2.50) | < .001 | 0.95 (0.43-2.11) | .910 |
| Haploidentical donor | 1.50 (1.14-1.98) | .004 | 1.27 (0.58-2.81) | .550 |
| GVHD prophylaxis | ||||
| CNI and MTX based | 1 | Ref | 1 | Ref |
| CNI and MMF based | 1.04 (0.88-1.23) | .650 | 1.10 (0.66-1.82) | .730 |
| PTCy | 1.23 (0.98-1.54) | .066 | 0.28 (0.13-0.57) | < .001 |
| Other | 1.22 (0.92-1.62) | .160 | 0.62 (0.30-1.32) | .220 |
| HCT-CI | ||||
| 0-2 | 1 | Ref | 1 | Ref |
| ≥3 | 1.01 (0.90-1.14) | .890 | 1.14 (0.84-1.54) | .400 |
| In vivo T-cell depletion | ||||
| No | 1 | Ref | 1 | Ref |
| Yes | 0.75 (0.65-0.87) | <.001 | 0.75 (0.47-1.21) | .240 |
| Donor source | ||||
| Bone marrow | 1 | Ref | 1 | Ref |
| Peripheral blood | 1.06 (0.90-1.24) | .500 | 1.26 (0.77-2.08) | .360 |
| Conditioning | ||||
| MAC (TBI < 8 Gy) | 1 | Ref | 1 | Ref |
| MAC (TBI ≥ 8 Gy) | 1.09 (0.90-1.31) | .370 | 1.21 (0.65-2.26) | .550 |
| RIC | 0.74 (0.65-0.84) | < .001 | 1.61 (1.13-2.31) | .008 |
| CNI discontinuation by day 100 | ||||
| Discontinued | 1 | Ref | ||
| Continued | 1.00 (0.55-1.84) | .990 | ||
| . | Classic . | Late . | ||
|---|---|---|---|---|
| HR (95% CI) . | P value . | HR (95% CI) . | P value . | |
| Recipient age (y), category | ||||
| <55 | 1 | Ref | 1 | Ref |
| ≥55 | 1.00 (0.87-1.16) | .960 | 1.84 (1.19-2.88) | .007 |
| Sex mismatch | ||||
| Other | 1 | Ref | 1 | Ref |
| Female-to-male | 0.98 (0.83-1.15) | .780 | 1.53 (1.09-2.14) | .014 |
| Primary disease | ||||
| Acute leukemia | 1 | Ref | 1 | Ref |
| MDS/MPN | 1.12 (0.97-1.28) | .120 | 1.02 (0.73-1.41) | .920 |
| Malignant lymphoma | 1.08 (0.87-1.34) | .480 | 1.00 (0.54-1.84) | .990 |
| Other | 1.00 (0.82-1.22) | .530 | 1.02 (0.61-1.70) | .930 |
| Disease risk | ||||
| Standard | 1 | Ref | 1 | Ref |
| High | 1.05 (0.91-1.21) | .530 | 0.89 (0.58-1.35) | .570 |
| Donor type | ||||
| HLA-MRD | 1 | Ref | 1 | Ref |
| HLA-MUD | 1.56 (1.34-1.81) | < .001 | 0.77 (0.55-1.07) | .120 |
| HLA-MMUD | 1.97 (1.55-2.50) | < .001 | 0.95 (0.43-2.11) | .910 |
| Haploidentical donor | 1.50 (1.14-1.98) | .004 | 1.27 (0.58-2.81) | .550 |
| GVHD prophylaxis | ||||
| CNI and MTX based | 1 | Ref | 1 | Ref |
| CNI and MMF based | 1.04 (0.88-1.23) | .650 | 1.10 (0.66-1.82) | .730 |
| PTCy | 1.23 (0.98-1.54) | .066 | 0.28 (0.13-0.57) | < .001 |
| Other | 1.22 (0.92-1.62) | .160 | 0.62 (0.30-1.32) | .220 |
| HCT-CI | ||||
| 0-2 | 1 | Ref | 1 | Ref |
| ≥3 | 1.01 (0.90-1.14) | .890 | 1.14 (0.84-1.54) | .400 |
| In vivo T-cell depletion | ||||
| No | 1 | Ref | 1 | Ref |
| Yes | 0.75 (0.65-0.87) | <.001 | 0.75 (0.47-1.21) | .240 |
| Donor source | ||||
| Bone marrow | 1 | Ref | 1 | Ref |
| Peripheral blood | 1.06 (0.90-1.24) | .500 | 1.26 (0.77-2.08) | .360 |
| Conditioning | ||||
| MAC (TBI < 8 Gy) | 1 | Ref | 1 | Ref |
| MAC (TBI ≥ 8 Gy) | 1.09 (0.90-1.31) | .370 | 1.21 (0.65-2.26) | .550 |
| RIC | 0.74 (0.65-0.84) | < .001 | 1.61 (1.13-2.31) | .008 |
| CNI discontinuation by day 100 | ||||
| Discontinued | 1 | Ref | ||
| Continued | 1.00 (0.55-1.84) | .990 | ||
The number of events for classic and late acute GVHD was 1245 and 193, respectively.
HCT-CI, HCT-specific comorbidity index; MDS/MPN, myelodysplastic syndromes/myeloproliferative neoplasms; MMF, mycophenolate mofetil; MTX, methotrexate; TBI, total body irradiation.